Patents by Inventor Samir Roy

Samir Roy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sirtuin modulating compounds and applications thereof
    Patent number: 12215069
    Abstract: In one aspect, compounds modulating sirtuin activity are described herein. Sirtuin modulation by compounds described herein includes sirtuin activation and sirtuin inhibition. Modulation of sirtuin activity includes sirtuin activation and/or sirtuin inhibition. In some embodiments, a sirtuin modulating compound and/or salt thereof is of Formula I described herein.
    Type: Grant
    Filed: January 24, 2024
    Date of Patent: February 4, 2025
    Assignee: CODAGEN BIOSCIENCES, INC.
    Inventors: Célina Reverdy, Gaetan Gitton, Xiangying Guan, Indranil Adhya, Rama Krishna Dumpati, Samir Roy, Santu Chall, Anisha Ghosh, Gauthier Errasti, Thomas Delacroix, Raj Chakrabarti
  • SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF
    Publication number: 20240228431
    Abstract: In one aspect, compounds modulating sirtuin activity are described herein. Sirtuin modulation by compounds described herein includes sirtuin activation and sirtuin inhibition. Modulation of sirtuin activity includes sirtuin activation and/or sirtuin inhibition. In some embodiments, a sirtuin modulating compound and/or salt thereof is of Formula I described herein.
    Type: Application
    Filed: December 29, 2022
    Publication date: July 11, 2024
    Inventors: Célina Reverdy, Gaetan Gitton, Xiangying Guan, Indranil Adhya, Rama Krishna Dumpati, Samir Roy, Santu Chall, Anisha Ghosh, Gauthier Errasti, Thomas Delacroix, Raj Chakrabarti
  • Sirtuin modulating compounds and applications thereof
    Patent number: 12012370
    Abstract: In one aspect, compounds modulating sirtuin activity are described herein. Sirtuin modulation by compounds described herein includes sirtuin activation and sirtuin inhibition. Modulation of sirtuin activity includes sirtuin activation and/or sirtuin inhibition. In some embodiments, a sirtuin modulating compound and/or salt thereof is of Formula I described herein.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: June 18, 2024
    Assignee: CODAGEN BIOSCIENCES, INC.
    Inventors: Célina Reverdy, Gaetan Gitton, Xiangying Guan, Indranil Adhya, Rama Krishna Dumpati, Samir Roy, Santu Chall, Anisha Ghosh, Gauthier Errasti, Thomas Delacroix, Raj Chakrabarti
  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION
    Publication number: 20220117977
    Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 21, 2022
    Applicant: ALLERGAN SALES, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH
    Publication number: 20200061082
    Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 27, 2020
    Applicant: ALLERGAN SALES, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
    Patent number: 10500215
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: December 10, 2019
    Assignee: Allergan Sales, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH
    Publication number: 20190111063
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
    Patent number: 10137135
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: November 27, 2018
    Assignee: Allergan Sales, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • IMPROVED TOPICAL KETOPROFEN FORMULATIONS
    Publication number: 20180207094
    Abstract: A topical formulation comprising an oil-in-water (o/w) emulsion of ketoprofen in a racemic or (s)-enantiomer form is provided herein. In some embodiments, the topical formulation is a cream. In some embodiments, the topical formulation includes one or more oily substances, higher alcohols, drug solubilizing vehicles, surfactants, permeation enhancers, buffering agents, antioxidants, preservatives, and water.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 26, 2018
    Inventors: Samir Roy, Charlotte P. Clark
  • Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
    Publication number: 20070065494
    Abstract: Methods and formulations of enhancing the permeability the skin of a subject to a drug are disclosed. The method may include administering a combination of lauryl alcohol and isopropyl myristate as a penetration enhancer to the area of skin to provide synergistically enhanced penetration of the drug.
    Type: Application
    Filed: July 31, 2006
    Publication date: March 22, 2007
    Applicant: WATSON LABORATORIES, INC.
    Inventors: Angela Anigbogu, Samir Roy, Vesna Anteljevic
  • Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
    Publication number: 20070037780
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 15, 2007
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Topical treatment for prevention of ocular infections
    Patent number: 7056893
    Abstract: Azalide antibiotics such as azithromycin are useful in the treatment and prevention of infections by bacteria and other parasites. Stabilized aqueous compositions containing azithromycin suitable for administration without reconstitution are provided for. Also provided for are aqueous formulations suitable for ocular administration in a employing a convenient dosing formulation suitable for administration in depot formats.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: June 6, 2006
    Assignee: Insite Vision, Inc.
    Inventors: Samir Roy, Lyle M. Bowman
  • Quinolone carboxylic acid compositions and related methods of treatment
    Publication number: 20040157825
    Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Type: Application
    Filed: February 2, 2004
    Publication date: August 12, 2004
    Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
  • Quinolone carboxylic acid compositions and related methods of treatment
    Patent number: 6699492
    Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: March 2, 2004
    Assignees: InSite Vision Incorporated, SSP Co., Ltd.
    Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
  • Quinolone carboxylic acid compositions and related methods of treatment
    Patent number: 6685958
    Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Type: Grant
    Filed: April 25, 2001
    Date of Patent: February 3, 2004
    Assignees: InSite Vision Incorporated, SSP Co., Ltd.
    Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
  • Topical treatment or prevention of ocular infections
    Publication number: 20030143259
    Abstract: Azalide antibiotics such as azithromycin are useful in the treatment and prevention of infections by bacteria and other parasites. Stabilized aqueous compositions containing azithromycin suitable for administration without reconstitution are provided for. Also provided for are aqueous formulations suitable for ocular administration in a employing a convenient dosing formulation suitable for administration in depot formats.
    Type: Application
    Filed: June 4, 2002
    Publication date: July 31, 2003
    Inventors: Samir Roy, Lyle M. Bowman
  • Quinolone carboxylic acid compositions and related methods of treatment
    Publication number: 20020187193
    Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Type: Application
    Filed: April 25, 2001
    Publication date: December 12, 2002
    Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
  • Quinolone carboxylic acid compositions and related methods of treatment
    Publication number: 20020182255
    Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
    Type: Application
    Filed: April 22, 2002
    Publication date: December 5, 2002
    Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
  • Ophthalmic compositions
    Publication number: 20010029269
    Abstract: An ophthalmic composition containing a divalent salt and a non-steroidal anti-inflammatory agent as a precipitate. The composition reduces or eliminates the risk of stinging and burning the eye from topical application. Additionally a preservative system comprising a perborate salt, a polyphosphonic acid peroxy stabilizer and EDTA provides stable preservation of a variety of aqueous ophthalmic compositions.
    Type: Application
    Filed: May 24, 2001
    Publication date: October 11, 2001
    Inventors: Lyle M. Bowman, James F. Pfeiffer, Eric B. Memarzadeh, Samir Roy
  • Ophthalmic composition
    Patent number: 6265444
    Abstract: An ophthalmic composition containing a divalent salt and a non-steroidal anti-inflammatory agent as a precipitate. The composition reduces or eliminates the risk of stinging and burning the eye from topical application. Additionally a preservative system comprising a perborate salt, a polyphosphonic acid peroxy stabilizer and EDTA provides stable preservation of a variety of aqueous ophthalmic compositions.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: July 24, 2001
    Assignee: InSite Vision Incorporated
    Inventors: Lyle M. Bowman, James F. Pfeiffer, Eric B. Memarzadeh, Samir Roy